Andrew D. Seidman, MD

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Seidman says currently there is not a HER2 histochemical test for gene amplification or signatures to best select patients for either CDK46 or MTOR inhibitor, as well for PI3 kinase inhibition.

​Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the shift paradigm of breast cancer treatment and the development of targeted agents that disrupt certain pathways.

Andrew D. Seidman, MD, from Memorial Sloan-Kettering Cancer Center, discusses breast cancer treatment with surgery and radiotherapy.

Andrew D. Seidman, MD, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.